Students Research in Progress
Monday, November 13, 2023
01:00 PM–02:30 PM
Abstract
Introduction: Infectious Diseases Society of America guidelines for Candida urinary tract infections (UTI) recommend 14 days of antifungal treatment. For bacterial UTI, studies have demonstrated that shorter durations have comparable outcomes to longer antibiotic treatment durations. However, to our knowledge, there are no data to compare shorter (e.g., 7-10 days) versus longer (e.g., 14 days) antifungal treatment courses for Candida UTI.
Research Question or Hypothesis: Are clinical outcomes comparable between shorter versus longer antifungal treatment durations for Candida UTI?
Study Design: Single-center, retrospective, cohort study between 1/1/2015-1/1/2023.
Methods: Hospitalized patients eligible for inclusion are >18 years old with >1 urine culture with >1,000 cfu/ml Candida and symptoms (dysuria, increased frequency, increased urgency, fever, hematuria, costovertebral angle tenderness) who received >1 dose of antifungal therapy within 96 hours of urine culture collection. Patients are excluded if Candida is isolated from another culture site within 7 days of the urine culture result, received antifungal therapy within the preceding 7 days, did not have any UTI symptoms, had a diagnosis of vulvovaginal candidiasis, pregnant women, and incarcerated individuals. The primary outcome is to compare resolution of symptoms between shorter versus longer antifungal treatment durations for Candida UTI. Secondary outcomes include recurrence of symptoms within 30 days requiring antifungal retreatment, hospital readmission within 90 days of index culture (IC) due to Candida UTI, microbiological recurrence within 90 days of IC, and all-cause mortality within 90 days of IC. Statistical analyses will be performed using R (R Foundation for Statistical Computing, Vienna, Austria) including descriptive statistics. The ?2 or Fisher exact test and the Student t test or Mann-Whitney U test will be used for categorical and continuous data, respectively. All statistical tests will be 2-tailed, and a p-value less than 0.05 will be considered to indicate a statistically significant difference.
Results: In progress.
Conclusion: In progress.
Presenting Author
Jacob Govel PharmD CandidateBinghamton University
Authors
Wesley Kufel PharmD
Binghamton University School of Pharmacy and Pharmaceutical Sciences
Robert Seabury PharmD
State University of New York Upstate Medical University